PREDILIFE SA (ALPRE.PA) Stock Price, Forecast & Analysis
Europe - Euronext Paris - EPA:ALPRE - FR0010169920 - Common Stock
ALPRE.PA Key Statistics, Chart & Performance
The current stock price of ALPRE.PA is 3.17 EUR. In the past month the price decreased by -6.76%. In the past year, price decreased by -10.96%.
ALPRE.PA Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ARGX.BR | ARGENX SE | 68.41 | 44.56B | ||
| 1AE.DE | ARGENX SE | 68.47 | 44.60B | ||
| 22UA.DE | BIONTECH SE-ADR | N/A | 19.83B | ||
| 2X1.DE | ABIVAX SA | N/A | 8.92B | ||
| ABVX.PA | ABIVAX SA | N/A | 8.95B | ||
| GXE.DE | GALAPAGOS NV | N/A | 1.86B | ||
| GLPG.AS | GALAPAGOS NV | N/A | 1.86B | ||
| NANO.PA | NANOBIOTIX | N/A | 916.09M | ||
| 5CV.DE | CUREVAC NV | 6.69 | 873.21M | ||
| IVA.PA | INVENTIVA SA | N/A | 772.67M | ||
| PHIL.MI | PHILOGEN SPA | 20.35 | 678.37M | ||
| FYB.DE | FORMYCON AG | N/A | 461.19M |
Related stock screener links
About ALPRE.PA
Company Profile
Predilife SA operates as a medical technology company. The company is headquartered in Villejuif, Ile-De-France and currently employs 27 full-time employees. The company went IPO on 2018-12-21. The firm operates mainly in the field of oncology. Predilife offers MammoRisk, which is a predictive breast cancer test that combines medical imaging thanks to a proprietary software, DenSeeMammo, Big Data and statistics through a scoring tool and genetic profiles via a polygenic risk score (PRS). The image is analysed in order to extract the breast density and the first breast cancer risk factor. In addition, The technology used by MammoRisk makes it possible to evaluate from a database of individuals tracked over time, the risks of an individual to develop cancer compared to the fate of his/her closest neighbors through a database of a number of American and French women.
Company Info
PREDILIFE SA
Igr Campus Cancer 1 Batiment Maurice, 39 Rue Camille Desmoulins
Villejuif ILE-DE-FRANCE FR
Employees: 19
Phone: 33142114211.0
PREDILIFE SA / ALPRE.PA FAQ
Can you describe the business of PREDILIFE SA?
Predilife SA operates as a medical technology company. The company is headquartered in Villejuif, Ile-De-France and currently employs 27 full-time employees. The company went IPO on 2018-12-21. The firm operates mainly in the field of oncology. Predilife offers MammoRisk, which is a predictive breast cancer test that combines medical imaging thanks to a proprietary software, DenSeeMammo, Big Data and statistics through a scoring tool and genetic profiles via a polygenic risk score (PRS). The image is analysed in order to extract the breast density and the first breast cancer risk factor. In addition, The technology used by MammoRisk makes it possible to evaluate from a database of individuals tracked over time, the risks of an individual to develop cancer compared to the fate of his/her closest neighbors through a database of a number of American and French women.
What is the current price of ALPRE stock?
The current stock price of ALPRE.PA is 3.17 EUR. The price increased by 5.32% in the last trading session.
Does PREDILIFE SA pay dividends?
ALPRE.PA does not pay a dividend.
How is the ChartMill rating for PREDILIFE SA?
ALPRE.PA has a ChartMill Technical rating of 1 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
What is the GICS sector and industry of ALPRE stock?
PREDILIFE SA (ALPRE.PA) operates in the Health Care sector and the Biotechnology industry.
What is the employee count for ALPRE stock?
PREDILIFE SA (ALPRE.PA) currently has 19 employees.
What is PREDILIFE SA worth?
PREDILIFE SA (ALPRE.PA) has a market capitalization of 12.01M EUR. This makes ALPRE.PA a Nano Cap stock.
ALPRE.PA Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to ALPRE.PA. When comparing the yearly performance of all stocks, ALPRE.PA is a bad performer in the overall market: 78.18% of all stocks are doing better.
ALPRE.PA Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to ALPRE.PA. Both the profitability and financial health of ALPRE.PA have multiple concerns.
ALPRE.PA Financial Highlights
Over the last trailing twelve months ALPRE.PA reported a non-GAAP Earnings per Share(EPS) of -0.99. The EPS increased by 20.8% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -290.08% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
ALPRE.PA Forecast & Estimates
9 analysts have analysed ALPRE.PA and the average price target is 21.34 EUR. This implies a price increase of 573.14% is expected in the next year compared to the current price of 3.17.
For the next year, analysts expect an EPS growth of -10.83% and a revenue growth 50.7% for ALPRE.PA